Pharma Mar SA
Mr. Moreno has been the Director of Capital Markets and Investor Relations at PharmaMar since 2009. From 2002 until 2009, he was the co-founder and managing partner of the independent financial group Solventis. He previously headed equity sales at Banco Espirito Santo Investment for three years after holding the same position at Benito y Monjardín SVB. He started his career in 1994 working in the research and marketing department of the Spanish Futures and Options Exchange developing financial derivatives. Mr. Moreno graduated with a degree in Management and Business Administration from the University of Hertfordshire and has a degree in Business Administration from the University of Barcelona. He has an executive management program (PDG) from IESE and is also a Chartered Alternative Investment Analyst (CAIA). He has taught Masters courses on financial derivative products offered by the University of Barcelona, as well as other related courses at the Abat Oliba CEU University, the Center for Financial Studies and MEFF.
This person is not in any offices
Pharma Mar SA
Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.